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Abstract
Melatonin, more commonly known as the sleep hormone, is mainly secreted by the pineal gland in dark conditions and
regulates the circadian rhythm of the organism. Its intrinsic properties, including high cell permeability, the ability to
easily cross both the blood–brain and placenta barriers, and its role as an endogenous reservoir of free radical
scavengers (with indirect extra activities), confer it beneficial uses as an adjuvant in the biomedical field. Melatonin can
exert its effects by acting through specific cellular receptors on the plasma membrane, similar to other hormones, or
through receptor-independent mechanisms that involve complex molecular cross talk with other players. There is
increasing evidence regarding the extraordinary beneficial effects of melatonin, also via exogenous administration. Here,
we summarize molecular pathways in which melatonin is considered a master regulator, with attention to cell death
and inflammation mechanisms from basic, translational and clinical points of view in the context of newborn care.
Facts
● Melatonin is a ubiquitous molecule with natural and
powerful antioxidant proprieties and administration
of exogenous melatonin is safe
● Melatonin exerts anti-inflammatory effects mainly
by inhibiting inflammasome activation
● Melatonin exerts its antiapoptotic activities mainly
by blocking caspase 3 cleavage and mPTP opening
● “Oxygen radical diseases of neonatology” refers to
the oxidative stress that has a leading role in the
pathogenesis of neonatal morbidities and pathologic
conditions
Open questions
● How endogenous melatonin contrast the oxidative
stress that has a leading role in the pathogenesis of
neonatal morbidities and pathologic conditions?
● Which are the intracellular targets of melatonin?
● How could melatonin improve the treatment of
neonatal disease?
● What factors ultimately determine the melatonin
efficacy as an adjunctive treatment in sepsis, chronic
lung disease and hypoxic–ischemic encephalopathy
of the term and preterm infants
Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a ubi-
quitous molecule present in nature that carries out many
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functions1, manifesting enormous versatility and diversity.
More commonly known as the sleep hormone, melatonin
also has antioxidant, anti-inflammatory, antiapoptotic,
and many other crucial properties2,3. In mammals, this
multitasking indolamine is synthesized in the pineal gland
in a circadian manner in response to the photoperiodic
information received via the retinohypothalamic path-
way4,5. It is directly released into the bloodstream, where
it is distributed to all tissues6,7. Melatonin has two
important functional groups that determine its specificity
and amphiphilicity: the 5-methoxy group and the N-acetyl
side chain. In particular, due to its amphiphilic char-
acteristics, melatonin can diffuse and easily cross all
morpho-physiological barriers, such as the placenta or the
blood–brain barrier8,9, and it can enter all cells of the
body, influencing the function of a variety of tissues10.
Pineal synthesis is timed by the suprachiasmatic nucleus
of the hypothalamus, depending on the light–dark cycle
over a 24-h period5. Melatonin is mainly produced during
the dark phase, and the maximal plasma concentration of
this serotonin-derived hormone usually occurs 4–5 h after
darkness onset11. Light stimulus activates melanopsin
breakdown in retinal photoreceptive ganglion cells that,
via the retinohypothalamic pathway, induce the inhibition
of melatonin synthesis12; as a consequence, during the
daily light period, its level is low or even undetectable13.
Throughout life, melatonin levels tend to be significantly
reduced. In the blood, once secreted from the pineal
gland, melatonin is usually bound to albumin, metabo-
lized to 6-hydroxymelatonin by cytochrome P-450 iso-
forms and conjugated, in the liver, to produce the
principal urinary metabolite, 6-sulfatoxy-melatonin,
which is finally eliminated through the kidney14. However,
melatonin is not exclusively produced in the pineal gland,
but it is also locally synthesized in several cells and tissues,
such as the retina, the gastrointestinal tract, and the
innate immune system10. The synthesis in extrapineal
sites presumably does not follow circadian rhythms,
except for the retina, and mainly works as a local
antioxidant15,16.
Studies have proposed that mitochondria are the pri-
mary sites of melatonin synthesis17. Mitochondria are
major sources of free radicals, and in addition to being
commonly used to treat disoriented circadian clocks due
to jet lag and other disturbances (i.e., sleep inefficiency)18,
melatonin has been widely used as an antioxidative
therapy19 and its use dates back to 1993 (refs. 20,21). The
direct antioxidant and free radical scavenging properties
of melatonin are mainly due to its electron-rich aromatic
indole ring, which makes it a potent electron donor that
can significantly reduce oxidative stress3,22. Over this
direct action, melatonin can further activate melatonin
(MT) 1 and MT2 receptors (Fig. 1), upregulating anti-
oxidative defensive systems by increasing the expression
or activity of antioxidant enzymes such as superoxide
dismutase and glutathione peroxidase23.
MT1 and MT2 are seven transmembrane-spanning
proteins belonging to the G-protein-coupled receptor
(GPCR) superfamily24, which exhibit high-affinity binding
and could be activated at low concentrations of melatonin
(pM–nM)25. Furthermore, a third melatonin-binding site
(MT3) has been characterized and identified as the
cytosolic enzyme quinone reductase 2 (QR2), a known
detoxifying enzyme that reduces menadione and other
quinones26,27. Moreover, melatonin is also a ligand for
nuclear receptors, such as retinoid orphan receptors (or
retinoid Z receptors), ROR/RZRα, and ROR/RZRβ28–30
(Fig. 1).
Pathophysiological processes where melatonin
plays important roles
Antiapoptotic activity
Almost all the studies that monitored the melatonin-
dependent antiapoptotic activities include disease models
characterized by the presence of a hypoxic–ischemia (HI)
event. HI describes a pathological condition in which an
organ is subjected to harmful reduction in oxygen levels
(hypoxia) and a deficit in blood supply (ischemia). This
clinical picture entails the activation of several different
pathways, and melatonin is known to modulate most of
them, especially cell death. Mitochondria are organelles
with key functions in the adaptive and maladaptive
responses to brain injury31; indeed, they are strongly
involved in cell death pathways, such as apoptosis,
necrosis, and autophagy32, which cause an important
portion of neuronal damage in the perinatal HI event
(Fig. 2). In vitro experiments and neonatal animal models
of HI suggested a very complex network of cell death
cascades, highlighting a continuum from apoptosis to
necrosis33,34. In other words, the coexistence of necrotic
and apoptotic markers inside the same cell shape a het-
erogeneous phenotype characterized by a mixture of
suicide program activation33. In the immature brain of
rodents, the cell death continuum is more switched versus
apoptosis; indeed, HI drives cell death through Bcl-2
family members35,36. Under these conditions, mitochon-
dria permeabilize, and proapoptotic factors, such as
cytochrome c (Cyt C) and the apoptosis-inducing factor
(AIF), are released into the cytosol. Melatonin adminis-
tration reversed this phenotype by adopting a compen-
satory mechanism aimed at increasing Bcl-2 protein
expression, blocking Bax proapoptotic activity via the
SIRT1/NF-kB axis with a consequent and significant
inhibition of Cyt C release and the lack of apoptosome
formation and caspase 3 activation37 (Fig. 2). The AIF
pathway, together with increased levels of cleaved caspase
3, is recognized as the main inductor of apoptosis in the
damaged brain of neonatal rodents38, even if their action
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becomes less pronounced once the brain matures39.
Beneficial effects have also been reported by the use of
melatonin in brain-injured mice 24 h after reperfusion
with a selective action involving caspases 3 inhibition40.
Nevertheless, melatonin also contributes to antiapoptotic
activities via the Akt axis by preventing the decrease in
pAkt and pBad levels upon HI injury41,42 (Fig. 2).
Modulation of the permeability transition pore
Studies have reported that mitochondria permeabilize
due to the mitochondrial permeability transition pore
(mPTP) opening, a pathophysiological event that, under
favorable conditions, causes an increase in permeability of
the inner mitochondrial membrane and leads to mito-
chondrial depolarization, swelling, and the activation of
the apoptotic and necrotic pathways43; for these reasons,
mPTP is widely considered as the final step of cell
demise44. Even though the exact structure of the mPTP,
as well as its assembly kinetics, is still unknown, inter-
esting findings suggested that dissociation of F1FO ATP
synthase dimers45 and the c subunit pore-forming part46
have an important role in mitochondrial permeability
transition (mPT) and constitute a valid therapeutic
approach in pathologies subjected to widespread cell
death47,48. It is no coincidence that melatonin, in addition
to having a plethora of beneficial effects, executes neu-
roprotection by modulating mPTP activity49,50. Indeed,
melatonin is highly permeable to cell membranes and
easily crosses the blood–brain barrier51, ensuring a good
therapeutic profile for brain diseases, and is also able to
accumulate into mitochondria, probably via GLUT/
SLC2A and PEPT1/2 carriers52,53. Studies have shown
how its use in mitochondria isolated from rodent brains
and subjected to Ca2+-induced mPTP conferred protec-
tion from mitochondrial swelling and membrane depo-
larization49 and prevented Cyt C release and cardiolipin
peroxidation54 via mPTP inhibition (Fig. 2). Moreover, the
benefits of melatonin are appreciable in mitochondria
isolated from aged rodent brains where chronic treatment
allows for antiapoptotic effects and increased cellular
respiration as the young mitochondria counterparts. The
exact nature of this modulation (direct or indirect) is still
evolving. In 2004, Andrabi et al. claimed a direct inhibi-
tion of mPTP by melatonin55, but he never identified the
target pore protein; instead, a more recent study revealed
that melatonin-mediated mPTP inhibition would be
highly dependent on the MT1 receptor as mitochondrial
protective effects did not occur in the presence of luzin-
dole compound, an MT blocking agent56. Although
melatonin-dependent mPTP modulation has been widely
described with concordant results, related molecular
mechanisms have only been proposed. Zhou et al. pro-
posed two mechanisms by which (i) melatonin pretreat-
ment represents an interfering mechanism for Ripk3/
PGAM5/CypD axis execution, desensitizing cells to
necroptosis triggered by RipK3 activation, PGAM upre-
gulation, and CypD phosphorylation50 in endothelial cells;
and (ii) melatonin avoids mPTP opening and mitophagy-
mediated cell death by suppressing mitochondrial fission
following ischemia reperfusion injury that in turn restored
bound VDAC1-HK2 (ref. 57), limiting cell death in the
cardiac microvasculature. However, whether melatonin
plays the same role in HI brain injuries is unknown.
Modulation of autophagy
Autophagy is engaged in intracellular material recycling
to sustain cell bioenergetics58. The knowledge of mela-
tonin as an autophagy modulator derives mainly from HI
studies59–62. The interplay between melatonin and
autophagy is discordant; indeed, if some studies showed
that the hormone is able to significantly downregulate
autophagy in different disease models63–65, other reports
failed to confirm those findings, providing evidence for an
enhancement of the autophagic process upon melatonin
treatment66–68. Even when considering the same disease
picture, for instance, the perinatal HI event, studies have
shown how melatonin could prevent60 or enhance59 the
autophagic response to the pathologic insult (Fig. 2).
Regardless of how and in which way melatonin mod-
ulates autophagy, it has been confirmed as a very
important and functional protective agent69.
Fig. 1 Mechanisms of action of melatonin. Melatonin can exert its
effects by acting through receptor-independent mechanisms, which
involve the direct interaction of melatonin and other molecules, and
they are mainly related to its antioxidant and radical scavenging
action (a). As any other hormone, melatonin can also act through
specific cellular receptors, by membrane melatonin receptors, called
MT1 and MT2, which are seven transmembrane-spanning proteins
belonging to the G-protein-coupled receptor (GPCR) superfamily, by
the cytosolic enzyme QR2 (also called MT3), or through the nuclear
receptors RZR/ROR (b)
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Melatonin as a potent and widespread anti-inflammatory
agent
Several studies have shown that melatonin can regulate
the activation of the immune system, reducing chronic
and acute inflammation70–73.
Experimental and clinical data suggest that melatonin
exerts its anti-inflammatory effects by modulating both
pro- and anti-inflammatory cytokines in various patho-
physiological situations73,74. Since different cytokines are
associated with inflammatory diseases, wherein the bal-
ance between proinflammatory and anti-inflammatory
molecules determines the clinical outcome to some
degree, melatonin could modulate serum inflammatory
parameters. In addition, melatonin inhibits the expression
of cyclooxygenase (COX) and inducible nitric oxide syn-
thase (iNOS)75 and limits the production of excessive
amounts of prostanoids and leukotrienes and nitric oxide
(NO), as well as other mediators of the inflammatory
process, such as chemokines and adhesion molecules73,76
(Fig. 3).
In nonneuronal tissues, experimental studies have
demonstrated that melatonin inhibits NO production
induced by lipopolysaccharide (LPS) that induce the
activation of the immune response77. The addition of
melatonin, in a micromolar range, prevents LPS-induced
iNOS expression in cultured rat endothelial cells and
aortic rings77; this effect is not dependent on the activa-
tion of G-protein-coupled melatonin receptors but on
nuclear factor-kappa B (NF-κB)77. Indeed, NF-κB triggers
a cascade of molecular events, some of which may be
potential key targets for the treatment of inflammation,
and melatonin performs part of its anti-inflammatory
functions by modulating nuclear NF-κB transloca-
tion73,78,79. Furthermore, melatonin is mainly reported to
inhibit inflammasome activation70,80. Recently, Liu et al.80
demonstrated that this indole reduced LPS-induced
inflammation and thus NLRP3 inflammasome formation
in mouse adipose tissue by acting on the expression of
inflammasome genes, including NLRP3, ASC, and thereby
caspase-1 and IL-1β. In addition, the proinflammatory
form of cells, called pyroptosis, was also strongly inhibited
by melatonin80,81 (Fig. 3).
The anti-inflammatory properties of melatonin have
also been extensively studied in models of cardiac sep-
sis78,79,82, where melatonin blunted the NF-κB/NLRP3
connection and activation78,79,82. To conclude, and
Fig. 2 Antiapoptotic mechanisms operated by melatonin. Endogenous levels of melatonin and exogenous administration confer to injured cells
protection from many cell death forms including apoptosis, necroptosis, mPTP-driven cell death, and autophagy. Melatonin is high cell permeable
and its beneficial effects are mediated by both MT1/2-dependent and MT1/2-independent mechanisms. Once in the cytoplasm it blocks the Ripk3
cascade, Drp1 activation, and Bax-dependent cytochrome c (Cyt. C) release caused by external insults; as a result, the cell receives pro-survival signals.
Melatonin localizes also in mitochondria where PEPT1/2 and GLUT channels are postulated to be new transporters of this hormone in the organelle.
In mitochondria, melatonin modulates mitochondrial permeability transition pore (mPTP) opening and counteracts oxidative stress
Tarocco et al. Cell Death and Disease          (2019) 10:317 Page 4 of 12
Official journal of the Cell Death Differentiation Association
accordingly to the data summarized here, melatonin is
considered a potent molecule that has received increasing
attention in the management of a large variety of diseases
with an inflammatory etiology7,70–73,79 (Fig. 3).
Analgesic and others modulatory roles of melatonin
The molecular pathways underlying the analgesic action
of melatonin have not been completely addressed, and a
plethora of mechanisms have been proposed, such as
endorphin release from the pituitary gland83, modulation
of the central GABAergic system84, and additional inter-
action with multiple receptor types. Those ligand-target
bindings would include benzodiazepine, opioid, α(1)- and
α(2)-adrenergic, serotonergic and cholinergic receptors85
and, notably, the fascinating issue of the anti-nociceptive
role of melatonin seems to be mediated by MT1 and MT2
receptors themselves86,87,88. Studies have postulated that
the cause may be ascribed to the reduction in the excit-
ability of pain transmitting dorsal horn neurons via
hyperpolarization due to MT1/2-melatonin binding89.
Among the effects provided by melatonin administra-
tion, the modulation of N-methyl-D-aspartate (NMDA)
receptors and the conservation of myelin sheets in the
central nervous system (CNS) are probably the least
treated. NMDA receptors are sensitive to glutamate
binding, the major excitatory neurotransmitter in the
brain whose extracellular levels increase abnormally
during insults, such as ischemia. Excessive release of
glutamate and its binding with NMDA, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), or
kainite (KA) receptors promotes excitotoxicity cell injury
with a consequent activation of many molecular path-
ways, resulting in intracellular calcium (Ca2+) over-
load90,91, reactive oxygen species (ROS) production, mPT,
and cell swelling with brain edema92. Patch-clamp
experiments demonstrated how melatonin is able to
modulate NMDA receptor activity by the drastic
attenuation of their currents in neurons located in the
spinal cord dorsal horn93. Focused experiments con-
ducted in rat striatum synaptosome preparations have
reported that melatonin inhibits the excitatory response
in a partially Ca2+-dependent manner in which the direct
effect on membrane hyperpolarization promoted intra-
cellular Ca2+ influx reduction94. The involvement of
melatonin is dose-dependent, and if at physiological
concentrations, it inhibited NMDA-induced current. At
higher dosages, it also participated in the modulation of
AMPA-glutamate binding. It follows that melatonin
exerts powerful protective mechanisms against oxidative
damage and excitotoxicity mediated by glutamate
receptors95.
Melatonin as a neuroprotective agent was also recom-
mended in those pathologies involving white matter
damage96,97. Indeed, researchers have reported a plethora
of positive effects with different exposures of melatonin
following CNS trauma, such as axonal regrowth and
sprouting, conservation of a given thickness of myelin
sheet in oligodendrocytes, and improved nerve
maturation96,97.
As reported in the previous paragraphs, melatonin is a
widespread potent molecule that can reduce cellular
damage. Melatonin has recently received increased
attention for its enormous potential in a wide range of
different pathologies. In the next section, we discuss the
use of melatonin for newborn care.
Clinical utility in newborns
Oxidative stress has a leading role in the spectrum of
neonatal disease processes, and it has been known for
more than 160 years that hyperoxia has toxic effects on
different organs. Saugstad98 in 2005 talked about the
“oxygen radical disease of the newborn”: oxidative stress
may involve different organs, often simultaneously, giving
rise to different signs and different clinical manifestations.
Babies at birth are naturally exposed to the hyperoxic
challenge due to the transition from the hypoxic intrau-
terine environment (pO2 of 20–25mmHg) to extrauterine
life (pO2 of 100 mmHg). This transition naturally
increases oxidative stress, but the gap is even more sig-
nificant for infants that require resuscitation at birth with
supplemental oxygen. Newborns are often exposed to
oxygen therapies, have low antioxidant defenses despite
Fig. 3 Anti-inflammatory effects of melatonin. Melatonin is mainly
reported to possess anti-inflammatory properties by inhibiting
inflammasome activation, thus inhibiting caspase-1 activation,
cytokines release, and pyroptosis. In addition, melatonin can also
inhibit the expression of the cyclooxygenase (COX) and inducible
nitric oxide synthase (iNOS) by inhibiting nuclear NF-κB traslocation
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high levels of toxic radicals, and are more susceptible to
infections, especially if born prematurely99. Furthermore,
inflammation is strictly correlated with oxidative stress in
many conditions that affect newborns. To counteract free
radical damage, therapeutic strategies in preclinical and
clinical trials have tried to increase the antioxidant status
of term and preterm infants, and melatonin, which is safe,
nontoxic, and effective, has developed a leading role.
Indeed, the efficacy of melatonin has been tested against
the “oxygen radical diseases of newborn”, giving promis-
ing results100–102 (Fig. 4).
Melatonin and sepsis
Sepsis is a major cause of morbidity and mortality in
newborns, born both preterm and at term, with an inci-
dence of 1–10 cases per 1000 live births and a mortality rate
as high as 20% observed in very preterm newborns103.
Although improvements in neonatal care have decreased
the impact of early-onset sepsis in term infants, preterm
babies remain at high risk for both early-onset and late-
onset sepsis and their sequelae. According to the guidelines
of the International Pediatric Sepsis Consensus Con-
ference104, neonatal sepsis is defined as a clinical syndrome
characterized by the presence of both infection and sys-
temic inflammatory response syndrome (SIRS) and can
cause severe neurological complications due to brain
infection, as well as secondary hypoxemia resulting from
septic shock, pulmonary hypertension and severe lung
disease.
Clinically, SIRS includes respiratory symptoms, ranging
in severity from mild tachypnea to respiratory failure,
persistent pulmonary hypertension, irritability, lethargy,
temperature instability, poor perfusion and hypotension,
disseminated intravascular coagulation, poor feeding,
vomiting and ileus. CNS involvement may presents with
seizures, apnea, and depressed sensorium. It is accepted
that bacterial infection induces sepsis via the production
of endotoxins and the process is maintained by the
inflammatory cascade and oxidative mechanisms that,
once activated, operate independently from the presence
of pathogens103. Intracellular redox changes are involved
in the neonatal sepsis redox cycle and represent the main
cause of cell dysfunction and mitochondria. As reported
by Bajčetić et al. in 2014 (ref. 105), the immature innate
immune system in neonates has a low capacity to generate
ROS, so pro-oxidative processes in neonatal sepsis are
limited to intracellular compartments of affected tissues.
Moreover, neonatal cells appear to compensate for the
infection-dependent mitochondrial dysfunction by extra-
mitochondrial ATP production, and proliferating cells are
particularly susceptible to apoptosis induced by oxidative
stress105. This explains a higher incidence of long-term
effects in neonatal sepsis survivors but also underlines the
importance of different strategies for sepsis treatment
Fig. 4 Clinical trial of melatonin in newborn care. Melatonin clinical trial in full term infants (blue), in preterm pathologies (purple) or both (green).
In yellow are reported studies of pharmacokinetic. HIE hypoxic–ischemic encephalopathy, IUGR intrauterine growth retardation, CLD chronic lung
disease, PVL periventricular leukomalcia
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both with antioxidant administration and pharmacologic
inhibition of pro-oxidant pathways in addition to
antibiotics.
Endogenous blood melatonin concentrations are higher
in newborns with late-onset sepsis106, and its use as an
adjuvant therapy in the treatment of sepsis is associated
with improvement of clinical and laboratory outcomes107.
In 2018, El-Gendy et al.108 published a study about the
beneficial effect of melatonin in the treatment of neonatal
sepsis that involved 40 septic neonates and concluded that
the group who received melatonin had a significant
improvement in clinical condition and serum parameters
compared with the control group.
The review and meta-analysis of Henderson et al.
enrolled 120 ill newborns from three different studies who
were treated with melatonin as adjunctive therapies for
sepsis. The results revealed statistically significant mean
differences in C-reactive protein serum levels between
groups at 24 h postadjunctive therapy with melatonin and
a significant improvement of clinical condition in neo-
nates from the intervention group compared to the con-
trol group within 3 days of therapy109. Based on
clinicaltrial.gov, the recruitment phase of a randomized
study aimed to assess the efficacy of melatonin as an
adjuvant in the treatment of free radicals in septic preterm
infants compared to the conventional approach alone was
completed in Egypt (NCT03295162).
In conclusion, the use of melatonin as an adjunctive
therapy for sepsis treatment significantly reduced
inflammatory biomarkers and improved clinical condi-
tions in neonates, but larger scale studies with higher
validity are needed to demonstrate clear clinical benefits
of the therapy103,105,107–109.
Melatonin and preterm morbidity
As previously mentioned, oxidative stress has a leading
role in the pathogenesis of preterm morbidities and
pathologic conditions. Bronchopulmonary dysplasia
(BPD), retinopathy of prematurity, intraventricular
hemorrhage, and periventricular leukomalacia are only
some examples110. Oxygen therapies used both in the
delivery room and during hospitalization, immature organ
development, and inflammatory/infective complications
make the condition of preterm birth vulnerable to tissue
injury111,112. Soon, melatonin could be used in preterm
infants in the near future113,114, with the role of protective
molecule against oxidative stress.
In addition, Gitto et al. in 2012 published a study sug-
gesting a role for melatonin as an analgesic therapy during
procedural pain in preterm babies, especially when
inflammation is present. The Premature Infant Pain
Profile score (PIPP score) was lower in 30 infants treated
with common sedation plus melatonin during intubation
and mechanical ventilation than in those treated with
common therapy alone115. Likewise, the use of melatonin
has rapidly spread; some authors proposed it for preterm
babies affected by necrotizing enterocolitis116, for hemo-
lytic hyperbilirubinemia-induced oxidative brain
damage117, intrauterine fetal growth retardation118–121,
chronic lung disease (CLD), and periventricular leuko-
malacia. Notably, melatonin did not reveal any side effects
after single-dose administration to preterm babies born
before 31 weeks of gestational age GA (for details, MIND
phase II trial, NCT00649961).
Merchant et al.122 showed the difference between the
pharmacokinetic profile in preterm babies and adults
caused by immature liver and poor renal excretion and
concluded that a 2-h infusion of 0.1 μg/kg/h increased
plasma melatonin from undetectable to approximately
peak adult concentration. The principal research objective
of this multicenter double-blinded randomized placebo
controlled trial was to determine the dose required to
achieve physiological melatonin blood levels in preterm
infants, similar to that of the mother and to define its
pharmacokinetic profile in preterm infants. Additionally,
in 2017, Carloni et al.123 showed the difference between
pharmacokinetic profiles in premature newborns com-
pared with adults, and despite the small sample size, they
concluded that it is possible to obtain and maintain high
serum concentrations using a single administration of
melatonin repeated every 24/48 h.
Periventricular leukomalacia
Periventricular leukomalacia (PVL) is a diffuse damage
of the cerebral white matter that extends beyond the
periventricular regions found predominantly in preterm
infants.
PVL is due to three main mechanisms: hypoxia/ische-
mia of the vascular border zone, inflammation, excito-
toxicity and free radical attack. Furthermore, diffuse
lesion of PVL affects oligodendrocytes, which are the
most vulnerable cells to injury with resulting myelin
loss124.
Melatonin could be considered as the first candidate for
clinical trials of neuroprotection in preterm infants,
thanks to the peculiarity of easily crossing the placental
barrier and its effect in improving myelin content and
oligodendroglia cell maturation125,126. PRIMELIP, a mul-
ticenter therapeutic trial (NCT02395783), tested its neu-
roprotective action when administered in the immediate
prepartum period in very preterm infants.
Chronic lung disease
BPD, also known as CLD, is an important cause of
respiratory illness in preterm newborns that results in
significant morbidity and mortality. The epidemiology
and pathology of BPD have changed over the past 50
years. “Old” BPD occurred in preterm infants with
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surfactant deficiency following respiratory distress syn-
drome (RDS). These infants required ventilatory support
and high concentrations of supplemental oxygen thera-
pies that induced lung damage with regions of atelectasis
and regions of hyperinflation, epithelial injury, hyperplasia
of airway smooth muscle, fibrosis, and pulmonary vas-
cular hypertension. The improvement of neonatal RDS
management as surfactant administration, antenatal glu-
cocorticoid therapy, and less aggressive mechanical ven-
tilation significantly decreased the morbidity and
mortality of RDS and BPD in this population, shifting the
demographics of BPD to earlier preterm infants
(<29 weeks GA). As a consequence “new” BPD occurred
at extremely low GA and is characterized by arrested
alveolar-capillary development with larger, simplified
alveoli; increased interstitial fibrosis and abnormal pul-
monary vasculature; increased permeability with imma-
ture mechanisms for clearance of lung liquid; and
recruitment of macrophages and neutrophils. These
extremely low GA infants may not have surfactant defi-
ciency or RDS but instead have early requirements for
oxygen and ventilatory support due to multiple factors
leading to “respiratory instability of prematurity”127–129.
The management of RDS includes the prevention of
hypoxemia and acidosis, the optimization of fluid man-
agement, the reduction in metabolic demands, the pre-
vention of lung atelectasis and pulmonary edema, the
reduction in lung damage due to aggressive mechanical
ventilation, and the use of antioxidant strategies to
minimize oxidant lung injury. Several investigators have
reported that aggressive ventilatory strategies and oxygen
therapy are the most important risk factors for lung dis-
ease. If oxygen radical-damaged tissues are present the
premature lung is deficient in its antioxidant capacity. It
follows that after oxygen injury, the inflammatory reaction
develops, and IL1-β, IL-6, TNF-α and IL-8 are found in
higher concentrations in babies who developed
CLD130,131.
Furthermore, mechanical ventilation is a risk factor for
cerebral inflammation and brain injury due both to the
pulmonary inflammatory cascade, which migrates sys-
temically to the brain, and to hemodynamic instability for
the reduction in cardiac output and high pulmonary
resistance caused by the distension of alveoli and com-
pression of pulmonary capillaries132.
Gitto et al. published two studies in which approxi-
mately 100 newborns treated with melatonin as adjuvant
antioxidant therapies of RDS were compared to 100
newborns conventionally treated. The authors concluded
that melatonin treatment reduced proinflammatory
cytokines in tracheobronchial aspirate, serum nitrite/
nitare levels, and improved outcome because of its anti-
oxidative actions130,131. Further studies are needed to
investigate the possible use of melatonin as a preventive
strategy of oxidative stress in preterm newborns. Thus,
the preliminary results, i.e., the safety profile with high
feasibility of administration, make melatonin a promising
therapy for the prevention of BPD.
Melatonin and asphyxiated term infants
Perinatal asphyxia refers to a condition during labor in
which impaired gas exchange leads to fetal hypoxemia and
hypercarbia. It is identified by fetal acidosis as pH < 7.0
and it is used in association with the neurological signs to
evaluate term newborn at risk for brain injury in the
perinatal period. The frequency of perinatal asphyxia is
approximately 2–3/1000 live births133. The neurodeve-
lopmental consequences of brain injury include death,
cerebral palsy, severe intellectual disabilities, blindness,
deafness, and a number of minor behavioral and cognitive
deficits. HI can develop acutely or chronically during the
prenatal (maternal factors such as hypotension, infection,
hypoxia), perinatal (umbilical cord accidents, uterine
rupture, placental factors), or postnatal period (shock,
anemia, respiratory, or cardiac arrest)134.
In the pathological changes of neonatal HI encephalo-
pathy (HIE), the time of injury and the time of treatment
play an important role because of the cascading reaction
process and cell changes. According to Wang, based on
significant differences in the pathophysiology and bio-
chemistry of brain tissues, it is possible to divide HIE into
three phases, all of which have apoptosis or necrosis of
nerve cells as the final outcome of brain damage135,136.
The primary energy failure phase (phase I) occurs 0–6 h
after HI injury. Because of hypoxia and acidosis in tissues
and organs, reduced myocardial contractility, decreased
arterial blood pressure, and reduced cerebral blood flow,
some cells undergo primary death based on the severity and
duration of HI. Clinically, the treatment strategies during
phase I utilize conventional methods: patients should be
treated with hypothermia, free radical scavengers (e.g., mel-
atonin, erythropoietin, coenzyme Q10), excitatory amino
acid receptor blocking agents, and/or neuroprotective agents.
The secondary energy failure phase (phase II) occurs
6–72 h after HI, and the deterioration of oxidative meta-
bolism has a leading role. Despite adequate oxygenation
and circulation, excitatory neurotransmitters and free
radicals continue to be released, phosphorus reserves are
depleted, inflammatory factors are involved, and brain
injury is substantial; as the time progresses, nerve cell
apoptosis begins. This phase is marked by the onset of
seizures, secondary to excitotoxic edema, cytokine accu-
mulation, and more serious mitochondrial dysfunction.
Therefore, the treatment strategies during phase II follow
the treatments employed during phase I: babies should be
treated with anti-inflammatory, neuroprotective, or nerve
regenerating agents (e.g., nerve growth factor), and stem
cell transplantation.
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The injury repair or chronic inflammation phase (phase
III) occurs days, months, and years after HI insult. Based
on the severity of the disease, the duration of HI and the
effects of prior therapeutic interventions, there are gen-
erally two outcomes: one involves recovery, where the
damaged brain tissue enters the repair process and the
surviving neurons and glial cells begin to differentiate,
proliferate, and regenerate; in the other outcome, the
injured tissue continues to deteriorate, and the mechan-
ism of the persisting damage involves gliosis with the loss
of support of neurotrophic factors, persistent inflamma-
tory receptor activation, and changes in microglia and
astrocytes that continue to release harmful cytokines,
which promote neuronal death and axonal injury. Even in
this case, the treatment should include anti-inflammatory
agents, neuroprotective agents, or nerve regenerating
agents (e.g., nerve growth factor) and stem cell trans-
plantation. Once the patient’s condition has stabilized, a
rehabilitation program should be planned for the patient
as early as possible135,137–139.
The literature reports that melatonin serum levels
increase after HI, such as the endogenous neuroprotective
response to brain injury135. Thus, melatonin appears to be a
good candidate for neuroprotection because of its safety
profile and different protective effects, including ROS
scavenging, excitotoxic cascade blockade, and modulation
of neuroinflammatory pathways140. In addition, if melatonin
is used in combination with hypothermia, the neuropro-
tective effects are greater than hypothermia alone134,141–146.
In 2015, Aly et al.147 published a randomized trial in which
the melatonin/hypothermia group, at 5 days of life, had
fewer seizures and fewer white matter abnormalities on
MRI. The limitation of that study was the small number of
patients, but the authors concluded that compared with
healthy neonates, the HIE group had increased melatonin,
SOD, and NO concentrations, and the combination of
melatonin to therapeutic hypothermia in infants with HIE
can improve neurodevelopmental outcome at 6 months of
age with effective effects in reducing oxidative stress in
terms of NO and SOD serum level reduction. Another
example comes from the studies by Fulia148 demonstrating
that melatonin exerted protective actions by reducing
malondialdehyde and nitrite/nitrate levels in newborn
blood, improving survival. More recently, Ahmad et al.149
published a randomized control trial using hypothermia or
hypothermia plus melatonin in 80 babies with HIE where
melatonin improved survival rate.
Based on clinicaltrial.gov, a dose escalation study to
evaluate the efficacy of enteral melatonin in infants with
HIE is underway (NCT02621944). The primary outcome
is to identify the maximum dose tolerated, and the second
aim is to evaluate neurological outcome.
A phase 3 trial to test the benefits of melatonin treat-
ment in association with hypothermia in infants with HIE
was withdrawn prior to enrollment in 2015
(NCT01904786). Another phase 1 and 2 trial was com-
pleted in Egypt to examine the effect of combining mel-
atonin with whole-body cooling on brain injury and the
outcome of neonates following perinatal asphyxia
(NCT02071160).
Conclusions
Few conclusive results are available from clinical trials
and from the literature (Fig. 4), despite encouraging data
regarding melatonin as an adjunctive treatment in neo-
natal disease, particularly in term infants with HIE.
The goals of future clinical trials should be to establish
the therapeutic range of melatonin dosage and the
appropriate timing of administration to improve clinical
condition and outcome.
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